explore -WSS

explore

author：comprehensive 2025-10-02 20:47:19 - browse：65828

When Prozac first entered the psychiatry scene in in the late ’80s, the profession was still Freud’s territory. Many considered taking medication to treat depression a failure. But that was all about to change, as early stewards like psychiatrist Peter Kramer refused to shy away from the new drug’s potential. These days, he says that people take for granted all of the progress that’s been made with antidepressant treatment in the past three decades.

“If you were going to be depressed any time in history and were interested in having an effective treatment, you would want to be alive now. But we’ve lost our wonderment about that,” said Kramer, the author of the groundbreaking 1993 book “Listening to Prozac.”

This week, Kramer joins me to discuss how the country’s relationship with antidepressants has changed since the publication of his book three decades ago. The conversation is based on his First Opinion, “What antidepressants are saying 30 years after the publication of ‘Listening to Prozac.’”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Apple is now the first public company to be valued at $3 trillion

WSS

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Dobbs anniversary: the lost opportunity of abortion as health care

Jerome Adams on the need for new antivirals for Covid

Why Sanofi got shellacked over its spinoff

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Paying for Covid pills will soon shift to insurers

explore

explore

knowledge

Walensky prepares to leave CDC — and Congress — behind

WHO may add ‘noma' to its list of neglected tropical diseases

Novavax promises a turnaround & Lilly roils the obesity market

Hepatitis C has a cure — but many Americans still lack access to it

In Memoriam: Notable people who died in 2023

Alkermes shareholders re

Medicare details structure of new drug price negotiation program

State Dept. review finds Biden bears some blame for Afghanistan failures

Anesthesiologist group: stop taking Ozempic before surgery

United colonoscopy coverage change 'may cost lives,' doctors say

explore

United colonoscopy coverage change 'may cost lives,' doctors say

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Diversifying clinical trials isn't enough to close racial gaps: study

Novavax promises a turnaround & Lilly roils the obesity market

Supreme Court strikes down use of affirmative action

explore

hotspot

explore

Wikipedia